27 results about "Exocrine secretion" patented technology

This invention relates to a method for producing chondroitin with improved safety and extracellular secretion levels, belonging to the field of genetic engineering. Using the probiotic *Escherichia coli* Nissle 1917 as the host, this invention designs methods to increase chondroitin production by studying the chondroitin synthase KfoAC and the chondroitin-linking Kdo synthase. The relationship between chondroitin synthesis and secretion in *E. coli* was clarified, and the specificity of the chondroitin-linking Kdo was investigated, resulting in an extracellular chondroitin production of 0.32 g / L. Subsequently, the introduction of the protein KfoB from the chondroitin synthesis gene cluster increased the extracellular chondroitin production to 0.51 g / L. Further screening and optimization of the expression of transport proteins resulted in an extracellular chondroitin production of 0.73 g / L in shake flasks. Further optimization using a 7-L fermenter resulted in an extracellular chondroitin production of 5.9 g / L.

The application provides a WNT5B-promoting tooth differentiation biological product and an application thereof. Compared with the prior art, the application has the following advantages: the patent integrates human embryonic tooth germ spatial transcriptome sequencing and epithelial cell and interstitial cell extracellular protein group sequencing data, screens signal molecules WNT5B and CTNNB1 secreted in the development process of tooth germ epithelium, and confirms the important role of WNT5B protein in tooth germ development for the first time. Compared with other WNT family members, WNT5B has stronger tooth-forming ability of promoting tooth-derived stem cells; the effective concentration of WNT5B is low, and 10 ng / ml is the optimal concentration of WNT5B for promoting tooth-derived stem cells to form teeth; and the role of WNT5B and CTNNB1 in extracellular secretion of tooth germ epithelial cells and the synergistic effect of WNT5B and CTNNB1 in promoting tooth differentiation of tooth germ mesenchymal cells are further determined, that is, the combined low-concentration use effect of the two is better than the single high-concentration use.

Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor.The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

A method of treating exocrine pancreatic insufficiency includes administering to an individual in need thereof (e.g., an individual with cystic fibrosis) an effective amount of an enteral composition having a total protein consisting essentially of hydrolyzed protein and a total fat containing monoacylglycerols (MAG) that are at least about 30 wt. % of the total fat, and the total fat optionally further contains medium chain triglycerides (MCT) and / or fatty acids. In one particular non-limiting embodiment, about 60 wt. % of the total fat is from MCT and about 40 wt. % of the total fat is from MAG; in another particular non-limiting embodiment, the total fat is MAG with free fatty acids (esterified and / or bound) without MCT; and in yet another particular non-limiting embodiment, the total fat is MAG alone without MCT.

According to the pancreas exocrine function in-vivo high-resolution monitoring system and monitoring method provided by the invention, exciting light emitted by a laser module (1) is reflected by a scanning galvanometer (21) and then is transmitted through a dichroscope (22); the femtosecond pulse exciting light passing through the dichroscope (22) is focused on a pancreas sample arranged on the objective table (24) by the objective lens (23) and excites a tryptophan two-photon fluorescence signal in the pancreas sample, and the tryptophan two-photon fluorescence signal is collected by the objective lens (23); after being reflected by the dichroscope (22), the femtosecond pulse exciting light is separated from the femtosecond pulse exciting light and then detected by the detector (25), so that a two-photon fluorescence image of tryptophan in the pancreatic sample is obtained, and tryptophan two-photon fluorescence can display pancreatic adenosine zymogen particles. The tryptophan two-photon fluorescence signal is used for carrying out delayed dynamic imaging on a pancreas sample, so that in-vivo, three-dimensional and high-resolution characterization of the pancreas zymogen particle number, distribution polarity, movement tendency and other characteristics can be reflected, and the pancreas exocrine function of the organism can be reflected in real time.

FIELD: veterinary medicine and dietetics.SUBSTANCE: development of complete feed compositions that can provide a therapeutic effect in cases of exocrine pancreatic insufficiency. The composition of a complete dietary feed for cats with exocrine pancreatic insufficiency has been developed in the following ratio, wt.%: grain part: mixture of rice, wheat, hulled barley and corn – 37.0; protein part of plant origin: isolated soy protein, beet pulp, wheat bran, flax seeds – 22.0; protein part of animal origin: feather meal, chicken liver, egg powder – 25.0; mineral supplement: feed chalk, monocalcium phosphate, table salt, plantain seeds Plantago psyllium, mannanoligasaccharides with beta-glucans and lutein – 2.0; vitamin premix: A, D3, E, K, B1, B2, B3, B5, B6, B12, Bc, H, taurine, inulin, beech lignocellulose, complex of natural fulvic and humic acids – 2.5; flavor enhancer in the form of enzymatic hydrolysate of pork and chicken by-products – 3–3.5; brewer's yeast – 2.5–3.0; a mixture of fish and chicken fat – 5.0–6.0.EFFECT: obtaining food for cats with exocrine pancreatic insufficiency, which is easily reproducible, clinically effective, and convenient in dosing and use.1 cl, 3 tbl, 1 ex

The separation and detection method comprises the following steps: rinsing placenta or villus tissues in a PBS (Phosphate Buffer Solution) added with a 1% penicillin-streptomycin double antibody solution, digesting the placenta or villus tissues into single cells by using a 1640 culture medium containing I-type and IV-type collagenase after the placenta or villus tissues are rinsed sufficiently to obtain a cell suspension, and culturing the cell suspension for later use; diluting and neutralizing collagenase digestive juice by using a 1640 culture medium containing high-temperature heat-inactivated fetal calf serum according to 5 times of volume; repeatedly discarding the precipitate, recovering the supernatant, and centrifuging to obtain a coarse migration body; and establishing a density gradient by using Optiprep as a density medium, washing the precipitate with PBS, and centrifuging to obtain the trophoblast cell-derived transporter. The invention provides a group of placenta villus trophoblast cell source migration body specific expression membrane proteins for the first time, and provides a method for specifically capturing the placenta trophoblast source migration body on the basis of the placenta villus trophoblast cell source migration body specific expression membrane proteins, so that a new direction for researching a trophoblast dysfunction related disease mechanism can be enriched.

The present disclosure provides an expression vector and a method for generating the expression vector. The expression vector includes one or more inserted foreign DNA sequences, including human growth hormone (hGH) and a plurality of therapeutic genes, where the one or more inserted foreign DNA sequences are fused with intracellular or extracellular secretion sequences; a promoter, configured to drive expression of the one or more inserted foreign DNA sequences; an insulator, configured for stable and safety expression of the one or more inserted foreign DNA sequences; a marker gene, configured to encoding one or more corresponding proteins to indicate the expression of the one or more inserted foreign DNA sequences; and a regulator element, configured to control expression of the hGH and the plurality of therapeutic genes under a controllable condition.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

The present patent application discloses a kind of recombinant collagen VII and its preparation method and use.The recombinant collagen VII is obtained by multiple repetitions of short amino acid sequence GLPGAKGEKGAP.The secretory yield of the recombinant collagen VII in commercialized pichia expression system can be as high as about 17.3g / L, the extracellular secreted protein is basically not degraded during fermentation process, and more than 90% purity can be achieved by simple ultrafiltration and decolorization, industrial production can be realized;Moreover, the recombinant collagen VII has more optimal biological activities of promoting autophagy, improving endoplasmic reticulum stress state, promoting collagen secretion and inhibiting matrix metalloproteinase degradation of collagen, and shows good firming and anti-wrinkle effects.

This invention relates to bifunctional compounds and the use of such bifunctional compounds to reduce plasma levels of extracellular target molecules via lysosomal degradation. These bifunctional compounds have cell surface receptor ligands covalently linked to ligands capable of binding to extracellular target molecules (such as growth factors, cytokines, chemokines, hormones, neurotransmitters, capsids, soluble receptors, extracellular secretory proteins, antibodies, lipoproteins, exosomes, viruses, cell or plasma membrane proteins), wherein said cell surface receptors are associated with receptor-mediated endocytosis, including lysosomal degradation mediated by desialylate glycoprotein receptor (ASGPR) and lysosomal degradation mediated by mannose-6-phosphate receptor (M6PR). Pharmaceutical compositions comprising such bifunctional compounds and methods of treating diseases or disorders mediated by extracellular molecules using such bifunctional compounds are also provided herein.

The invention discloses a method for improving secretory expression of expansin by bacillus subtilis and application of the method, and belongs to the technical field of biology. According to the invention, bacillus subtilis G600 capable of successfully secreting and expressing the expansin BsEXLX1 from bacillus subtilis is firstly constructed, the expression level of expansin protein is enhanced through a strong promoter P21 in the strain, and then the most suitable RBS and signal peptide combination is screened, so that the efficient secretory expression of the expansin is optimized, and finally the secretory expression level of the BsEXLX1 is improved by 3.5 times. The transformation method provided by the invention can promote the secretory expression of the expansin, lays a foundation for promoting the biosynthesis of the expansin by transforming bacillus subtilis in metabolic engineering, and has a very good application prospect. The expansin produced by the recombinant strain constructed by the invention is stable in protein expression and high in extracellular secretion amount, the construction method is simple and convenient to use, and a foundation is laid for further large-scale industrial production of expansin.

This invention relates to the field of vaccine technology and provides a CHO cell line for exocrine expression of PEDV GIIb subtype S protein and its application. The CHO cell line integrates a codon-optimized PEDV GIIb S protein encoding gene carrying the TPA signal peptide into its chromosome. The nucleotide sequence of the PEDV GIIb S protein encoding gene is shown in SEQ ID NO.1. This invention uses currently prevalent GIIb strains as the antigen source to ensure vaccine strain matching; it constructs a secretory expression structure, thereby significantly improving the exocrine expression efficiency of the S protein; it precisely truncates the transmembrane region while retaining key structural domains, maintaining the protein's native conformation and immunogenicity; and it obtains a CHO cell line with stable gene integration and long-term passage to maintain expression levels through optimized transfection conditions and an antibiotic selection system.

The invention discloses a method for simultaneously extracting various cells of internal and external secretion parts of pancreas, and relates to the technical field of pancreas islet separation and purification. The invention discloses a method for simultaneously extracting various cells of internal and external secretion parts of pancreas. The method comprises the following steps: exposing a target visual field, performing pancreas perfusion, terminating digestion, sieving, performing gradient centrifugation, observing and separating layered cells, sorting pancreas islets, extracting acinus cells and identifying. According to the method, a gradient centrifugation method is adopted, a density gradient environment is constructed through a gradient centrifugation solution based on the difference of different cell densities, and various cells settle to corresponding positions according to self densities, so that efficient separation of islet cells, alveolar cells and impurities (such as adipocytes, digestive enzymes and tissue fragments) is realized, and the separation efficiency of the islet cells, the alveolar cells and the impurities is improved. Finally, different types of cells are obtained, and various cell populations obtained based on the method are high in purity, good in activity and high in yield.

This invention relates to the fields of microbial fermentation and genetic engineering technology, specifically disclosing a method for preparing human type III collagen fragments. Based on Pichia pastoris, this invention constructs a multidimensional synergistic expression system of "molecular chaperone co-expression - precursor supply - osmotic pressure adaptation regulation," reducing the structural instability of collagen fragments during secretion and post-processing, and constructing an expression system suitable for stable and efficient secretion of collagen fragments. The method described in this invention can achieve efficient extracellular secretory expression of human type III collagen fragments, and the obtained protein has high structural uniformity and stability, with a protein yield of up to 6.55 g / L under 5 L fermenter conditions. The method described in this invention is suitable for the large-scale preparation of human type III collagen fragments and provides a new technical solution for obtaining collagen products with high structural uniformity and good functional activity.

In the field of medical device technology, we provide a pusher for nasal sprays for the exocrine system. [Solution] The device includes a drug solution bottle, a pressing component, an atomizing chamber 5, a microporous screen plate 6, and a nozzle component 7. The atomizing chamber is provided with a flow guide cone and an annular buffer chamber for guiding the drug solution and buffering the flow velocity. The microporous screen plate has uniformly distributed micropores and atomizes the drug solution into droplets with concentrated particle size. The nozzle component includes a throttling ring and an opening for restricting the initial spray velocity of the droplets and for ejecting them at an inclined angle. The coordination of these structures reduces the shear force generated on the exocrine system during the spraying process, improving consistency and dose reproducibility in the administration of exocrine nasal sprays. Conventional nasal spray devices are prone to structural damage during the spraying process for shear-sensitive substances such as exocrine systems, resulting in insufficient consistency and reproducibility of administration.

The invention relates to the technical field of screening and application of probiotics, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving inflammation and application of the bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis). The strain is separated from infant excrement, has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.34159, is acid-resistant and cholate-resistant, and has outstanding antibacterial and anti-inflammatory regulation capabilities. The strain can secrete an approximately circular or elliptical vesicle structure outside a cell. The vesicles can significantly inhibit lipopolysaccharide-induced macrophage M1 type polarization, regulate inflammatory factor balance and pancreatic function indexes, significantly improve pathological injuries of mice with acute pancreatitis, and have broad application prospects.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

This invention relates to the field of vaccine technology and provides a CHO cell line for the TGEV strain S protein and its application. The CHO cell line has a TGEV S protein encoding gene with codon optimization carrying the TPA signal peptide integrated into its chromosome. The nucleotide sequence of the TGEV S protein encoding gene is shown in SEQ ID NO.1. This invention not only significantly improves the exocrine expression efficiency and stability of the TGEV S protein but also increases protein quantity and yield, establishing an expression system that can operate stably for a long time and is suitable for large-scale production, demonstrating clear technological advancement and practical application value.

The invention discloses a plasmid for simultaneously realizing display and secretion, application of the plasmid, a system capable of simultaneously realizing display and secretion and a construction method of the system. The plasmid for realizing cell surface display and cell exocrine comprises a first FC protein coding region and a second FC protein coding region, the first FC protein coding region comprises a first signal peptide, a first FC protein region and an MCS region, the MCS region is used for accessing a target gene, and the second FC protein coding region comprises a second signal peptide, a second FC protein region and a transmembrane domain TM. By utilizing the dimer form of the FC fusion protein, on one hand, the antibody or the functional protein can be expressed on the cell surface, and on the other hand, the corresponding antibody molecule or the functional protein can be secreted in the culture supernatant at the same time.

To provide a method for improving pancreatic function.SOLUTION: The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and / or progeny cells thereof and / or soluble factors derived therefrom. The method of the invention is useful for treating and / or preventing and / or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.SELECTED DRAWING: None

The present disclosure provides a cancer treatment that uses an extracellular secretion. In a specific embodiment, the present disclosure provides a cancer treatment that uses a combination of an extracellular secretion and an ascorbic acid component. The present disclosure provides uses, methods, combinations, or compositions for the treatment of cancer. In one embodiment, the cancer may be breast cancer (including triple-negative breast cancer lacking estrogen receptors, progesterone receptors, and HER2). The subject to be treated includes mammals such as humans, mice, rats, cats, and dogs.

The present invention discloses a process for the secretion of brazzein in improved yield.

The present disclosure provides an extracellular secretion that is useful in the treatment of various diseases. In one embodiment, the present disclosure provides an extracellular secretion including approximately 6×1010 / mL or more small extracellular vesicles (sEVs). In one embodiment, the present disclosure provides an extracellular secretion including small extracellular vesicles (sEVs) having a particle size distribution in which the particle size mode is approximately 100 nm to approximately 120 nm. In one embodiment, the extracellular secretion is obtained from a culture supernatant of mesenchymal stem cells. In one embodiment, the extracellular secretion is used to treat aging.

The invention belongs to the technical field of food or medicine, and particularly relates to a buccal tablet and a preparation method thereof. The buccal tablet comprises a first supporting layer, a functional layer and a second supporting layer which are sequentially laminated, wherein the functional layer comprises an active substance, and the first supporting layer and the second supporting layer are both exocrine dissolving layers. The supporting layer in the buccal tablet is the exocrine dissolving layer and has a dissolving characteristic in saliva, so that the problem that the buccal tablet needs to be spitted after oral administration is solved, and the supporting layer also has an edible characteristic, so that discomfort and harm cannot be generated after unintentional swallowing.

The invention relates to the technical field of cell extraction, in particular to a pancreatic stellate cell acquisition method. The synergistic effect of Liberase MTF is utilized, the special collagenase I / II and neutral protease combination can specifically degrade pancreatic basilar membrane IV type collagen, density threshold value locking is carried out, the density difference between exocrine tissue and pancreas islet is utilized, a three-step gradient centrifugation method is developed, and the residual pressure of the pancreas islet is reduced to be smaller than 5%. According to the low-density inoculation theory, by controlling the tissue amount to be 0.3 ml / dish, cell function damage caused by local oxygen deficit is avoided.

To provide bifunctional compounds and use of such bifunctional compounds to lower plasma levels of extracellular target molecules with lysosomal degradation.SOLUTION: The bifunctional compounds have a ligand of a cell surface receptor covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds for use in the treatment of FHR3 mediated diseases or disorders are also provided.SELECTED DRAWING: None